Single molecule activating GLP-1 and APJ receptors improves metabolism, reduces abnormal blood fats, and normalizes liver fat and enzyme levels in high-fat diet mice

Dual activation of glucagon-like peptide-1 and apelin receptors may offer a new therapeutic approach for obesity and diabetes.

• The study focuses on the potential benefits of targeting both GLP-1 and apelin receptors in the treatment of metabolic disorders.
• Activation of these receptors is associated with improved regulation of appetite and glucose levels.
• This dual activation strategy could lead to enhanced therapeutic outcomes compared to current treatments.
• The findings suggest that this approach warrants further investigation in future studies.

Simplified